Replies to post #120806 on Biotech Values

[biomaven0]

I don't follow the company, but based on the abstract I assumed they were both their vaccines:

We examined patients from our E75 and vaccine X clinical trials.

If they aren't both RXII owned vaccines, then at least they seem to be similar:

E75 (HER2: 369-377) and another vaccine (X) are HLA-A2/3+-restricted peptides capable of stimulating CD8+ cytotoxic T cells with anti-HER2 tumor activity.

This company used to be a RNAi company, but I guess they have transformed themselves.

Peter